Condition: Triple Negative Breast Neoplasms · Sponsor: Merck Sharp & Dohme LLC
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| USA Mitchell Cancer Institute ( Site 0090) | Mobile, Alabama, United States | Recruiting |
| Ironwood Cancer & Research Centers ( Site 0036) | Chandler, Arizona, United States | Recruiting |
| City of Hope ( Site 0097) | Duarte, California, United States | Recruiting |
| City of Hope Lennar Foundation Cancer Center ( Site 0099) | Irvine, California, United States | Recruiting |
| UCLA Department of Medicine - Hematology & Oncology ( Site 0047) | Los Angeles, California, United States | Recruiting |
| UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0016) | San Francisco, California, United States | Recruiting |
| Yale New Haven Hospital ( Site 0001) | New Haven, Connecticut, United States | Completed |
| Washington Hospital Center ( Site 0098) | Washington D.C., District of Columbia, United States | Recruiting |
| AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0007) | Altamonte Springs, Florida, United States | Recruiting |
| Orlando Health Cancer Institute ( Site 0012) | Orlando, Florida, United States | Recruiting |
| Florida Cancer Specialists - East ( Site 7000) | West Palm Beach, Florida, United States | Recruiting |
| University Cancer & Blood Center, LLC ( Site 0023) | Athens, Georgia, United States | Recruiting |
+ 255 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06841354